SECOND MALIGNANCY AFTER CANCER TREATMENT

ESSAY

SUBMITTED TO FACULTY OF MEDICINE CAIRO UNIVERSITY
IN THE PARTIAL FULFILLMENT OF THE M.Sc. DEGREE IN
INTERNAL MEDICINE

616.994
Y. A.

BY

YASSER AHMED SALLAM
(M.B., B. Ch.)

61876

SUPERVISED BY

DR. MOHAMMED ALI SHARAF
PROF. AND CHAIRMAN OF
INTERNAL MEDICINE
FACULTY OF MEDICINE
CAIRO UNIVERSITY

DR.ZIKRI KHALIDZIKRI
PROF.AND HEAD OF MEDICAL
ONCOLOGY DEPART
NATIONAL CANCER INSTITUTE
CAIRO UNIVERSITY

DR. NASR MOHAMMED ALI
LECTURER OF MEDICAL ONCOLOGY
NATIONAL CANCER INSTITUTE
CAIRO UNIVERSITY

FACULTY OF MEDICINE

CAIRO UNIVERSITY

1995

Central Library - Ain Shams University

Central Library - Ain Shams University

بسم الله الرحمن الرحيم

Central Library - Ain Shams University

بسم الله الرحمن الرحيم

﴿ وقل رب زدني علما ﴾

صدق الله العظيم [طه ١١٤]

Central Library - Ain Shams University

Central Library - Ain Shams University

ACKNOWLEGMENT

Needless to say how inexplicably tremendous the efforts exerted by **Professor Dr. Mohammed Sharaf,** in assisting me to prepare this essay, as he is the one, who always helps without waiting any refund.

My deepest thanks, to **Professor Dr. Zikri Khalid Zikri,** the one behind the idea of this work, for his productive support and his efforts in updating the data included in this work. Also, I am greatly indebted to **Prof. Dr. Hussien Khalid and Prof. Dr. Somia Ezzat** for supplying me with a great deal of valuable data without which this work would have been defective.

Finally, I am extremely grateful to **Dr. Nasr M. Ali,** who made me fore armed against many pitfalls, let my knowledge level with latest. developments of the field and notivated me to continue.

To all of them. *Thank You.*

Central Library - Ain Shams University

Central Library - Ain Shams University

CONTENTS

	Page
- ACKNOWLDGEMENT.	I
- INDEX.	II-V
- LIST OF TABLES.	VI-VII
- LIST OF FIGURES.	VIII
- LIST OF ABBREVIATIONS.	IX-X
- INTRODUCTION.	1
* PRINCIPALS OF CHEMOTHERAPY:	5
- **Chemotherapeutic agents with carcinogenic potential.**	6
- Epipodophyllotoxin.	6
- Cyclophosphamide.	9
- Melphalan	10
- Chlorambucil	10
- Nitrogen Mustard	11
- Procarbazine.	12
- Nitrosoureas.	13
- Thiotepa.	13
* PRINCIPALS OF RADIOTHERAPY:	15
- **Radiation interaction with biologic material.**	16
- **Oxygen and radiation.**	19
- **Cell cycle and radiation response.**	20
- **Pharmacologic modifiction of radiation effects.**	21
- **High linear energy transfer radiation.**	21
- **Low carcinogenicity of electron beam radiation relative to Argon ions.**	21
- **Decreased risk of radiation associated second malignant neoplasms in actinomycin-D treated patients.**	22
* CARCINOGENESIS:	24
- **Definition.**	24
- **Stages of carcinogenesis.**	27
- **Chemical carcinogenesis.**	29
- **Retinoblastoma gene as a human cancer recessive (regulatory) suceptibility gene .**	30

Central Library - Ain Shams University

Central Library - Ain Shams University

- **Second primary neoplasms in patients with retinoblastoma.** 31
- **Chromosomal abnormalities in human leukemia as indicators of mutagenic exposure.** 32
- **Diseases predisposing to leukemia.** 33
- **Relationship of chromosomal alteration to gene expression in carcinognesis.** 36
- **Human cellular transforming genes and chromosomal changes.** 37
- **Protoncogenes and chromosomal alteration in carcinogenesis.** 38
- **Suceptibillty genes for breast cancer.** 39
- **Cyclins, cell cycle control and neoplasia.** 39
- **Cytogenetic characteristics of t-ANLL & MDS and preleukemia.** 41
- **Occurrance of favorable cytogenetics in patients with secondary leukemia.** 42
- **Low AGT activity in peripheral blood lymphocytes in patients with t-ANLL.** 42
- **Radiation carcinogenesis** 43
  - Molecular biology of radiation carcinogenesis 43
  - Role of oncogenes in radiation carcinogensis. 44
  - Role of suppressor genes in radiation carcinogensis. 45
  - Repair and misrepair in radiation induced neoplastic transformation. 47
  - Clinical aspects of radiation carcinogensis. 49

* SPECIFICITY OF CHEMOTHERAPY INDUCED CARCINOGENSIS 52
- **Testing antineoplatic agents for carcinogenic potential.** 53
- **Mutagenesis assays.** 55
  - Ames test. 55
  - Sister chromatid exchange. 56
  - Cell culture systems. 58
  - Animal studies. 60
- **Classification of antineoplastic agents.** 62
  - Old classifiction. 62
  - Recent classification. 62
- **Potential risk factors associated with development of second malignancy.** 63

Central Library - Ain Shams University

Central Library - Ain Shams University

- **Clinical study groups:** 63
  - Ovarian cancer group. 63
  - Breast cancer group. 64
  - Adjuvant chemotherapy for breast cancer. 65
  - Multiple Myeloma group. 65
  - Malignant lymphoma group. 66
  - GIT cancer group. 66
- **Target organ specificity of carcinogenic chemotherapeutic agents:** 67
  - Semustine (Methyl CCNU) and leukemia. 68
  - Chlorambucil. 69
  - Epipodophyllotoxins. 69
  - Melphalan and cyclophosphamide. 71
  - Cisplatinum. 72

* SECOND HEMOPOIETIC MALIGNANCIES: 73
- **Leukemia induced by cytotoxic drugs.** 73
  - Hodgkin's disease. 73
  - Non-Hodgkin's lymphoma. 77
  - Multiple Myeloma. 78
  - Chronic lymphatic leukemia. 80
  - Polycythemia vera. 80
  - Acute lymphoblastic leukemia. 81
  - Essential thrombocythemia. 82
  - Non-hemopoietic maligancies. 82
    - Breast cancer. 82
    - Lung cancer. 83
    - Ovarian cancer. 83
    - Other malignancies. 84
- **Leukemia following exposure to radio therapy for malignant disease.** 85
- **Donor cell relapse after BMT.** 86

* SECOND SOLID MALIGNANCIES AFTER CANCER TREATMENT: 87
- **Non-Hodgkin's lymphoma.** 87
- **Lung cancer as a second malignancy.** 89
- **Bladder cancers.** 90

Central Library - Ain Shams University

Central Library - Ain Shams University

- Thyroid cancer. 91
- Cutaneous malignant melanoma. 92
- Breast cancer as second malignancy. 92
- Hodgkin's disease. 93
- Multiple Myeloma. 93
- Adenocarcinoma of stomach. 94
- Osteogenic sarcoma. 94
- Solid secondary cancers following treatment of hemopoietic disorders. 95

* ADJUVANT CHEMOTHERAPY; BENEFITS VERSUS CARCINOGENICITY. 98
* POTENTIAL OF SOME ENDOCRINAL TREATMENTOF CANCER TO INDUCE SECOND CANCER. 104
  - Tamoxifen. 104
* PREVENTION OF SECOND CANCERS. 105
* TREATMENT OF SECONDARY LEUKEMIA. 107
* SUBSTITUTIVE MODALITIES OF CANCER TREATEMEN. 111
  - Principals of Immunotherapy of cancer. 111
  - Immunotoxin therapy of cancer. 117
  - Gene therapy of cancer. 119
  - Antisense inhibition of Gene expression. 124
  - Use of Differentiating agents. 126
* REVIEW OF SOME COLLECTED CASES FROM NCI OF CAIRO. 129
* SUMMARY. 131
* REFERENCES. 134
* ARABIC SUMMARY.

Central Library - Ain Shams University

Central Library - Ain Shams University